Catalyst Pharmaceuticals - Public Comps and Valuation Multiples

Catalyst Pharmaceuticals Overview

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Founded

2006

HQ

Employees

181

Website

catalystpharma.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $571M

LTM EBITDA $272M

EV

$2.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Catalyst Pharmaceuticals Financials

As of November 2025, Catalyst Pharmaceuticals reported last 12-month revenue of $571M and EBITDA of $272M.

In the same period, Catalyst Pharmaceuticals generated $486M in LTM gross profit and $198M in net income.

See Catalyst Pharmaceuticals valuation multiples based on analyst estimates

Catalyst Pharmaceuticals P&L

In the most recent fiscal year, Catalyst Pharmaceuticals reported revenue of $492M and EBITDA of $233M.

Catalyst Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Catalyst Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$571M	XXX	$492M	XXX	XXX	XXX
Gross Profit	$486M	XXX	$423M	XXX	XXX	XXX
Gross Margin	85%	XXX	86%	XXX	XXX	XXX
EBITDA	$272M	XXX	$233M	XXX	XXX	XXX
EBITDA Margin	48%	XXX	47%	XXX	XXX	XXX
EBIT	$239M	XXX	$195M	XXX	XXX	XXX
EBIT Margin	42%	XXX	40%	XXX	XXX	XXX
Net Profit	$198M	XXX	$164M	XXX	XXX	XXX
Net Margin	35%	XXX	33%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Catalyst Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $571M. EBITDA for the last twelve months was $272M. In the most recent fiscal year, Catalyst Pharmaceuticals achieved $492M in revenue and $233M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$571M	Analyst estimates available to subscribers	$492M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$486M	Analyst estimates available to subscribers	$423M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	85.1% gross margin	Analyst estimates available to subscribers	86.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$272M	Analyst estimates available to subscribers	$233M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	47.6% EBITDA margin	Analyst estimates available to subscribers	47.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$239M	Analyst estimates available to subscribers	$195M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	41.9% EBIT margin	Analyst estimates available to subscribers	39.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$198M	Analyst estimates available to subscribers	$164M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	34.6% net profit margin	Analyst estimates available to subscribers	33.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Catalyst Pharmaceuticals

This financial data table provides comprehensive performance metrics for Catalyst Pharmaceuticals, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Catalyst Pharmaceuticals generated $571M in revenue over the last twelve months.
The company achieved $272M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $486M.
Net income over the last twelve months reached $198M.

Fiscal Year Performance

In the most recent fiscal year, Catalyst Pharmaceuticals reported $492M in total revenue.
Fiscal year EBITDA was $233M.
The company maintained a gross profit margin of 86.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 47.4%.
Net profit margin reached 33.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Catalyst Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals has current market cap of $2.8B, and EV of $2.2B.

Market Cap Evolution

Catalyst Pharmaceuticals Stock Data

As of December 4, 2025, Catalyst Pharmaceuticals's stock price is $23.

See Catalyst Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.2B	$2.8B	XXX	XXX	XXX	XXX	$1.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Catalyst Pharmaceuticals Valuation Multiples

Catalyst Pharmaceuticals's trades at 4.4x EV/Revenue multiple, and 9.2x EV/EBITDA.

See valuation multiples for Catalyst Pharmaceuticals and 15K+ public comps

Catalyst Pharmaceuticals Financial Valuation Multiples

As of December 4, 2025, Catalyst Pharmaceuticals has market cap of $2.8B and EV of $2.2B.

Equity research analysts estimate Catalyst Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Catalyst Pharmaceuticals has a P/E ratio of 14.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.8B	XXX	$2.8B	XXX	XXX	XXX
EV (current)	$2.2B	XXX	$2.2B	XXX	XXX	XXX
EV/Revenue	3.8x	XXX	4.4x	XXX	XXX	XXX
EV/EBITDA	7.9x	XXX	9.2x	XXX	XXX	XXX
EV/EBIT	9.0x	XXX	11.0x	XXX	XXX	XXX
EV/Gross Profit	4.4x	XXX	n/a	XXX	XXX	XXX
P/E	14.4x	XXX	17.3x	XXX	XXX	XXX
EV/FCF	9.6x	XXX	9.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Catalyst Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Catalyst Pharmaceuticals Margins & Growth Rates

Catalyst Pharmaceuticals's last 12 month revenue growth is 8%

Catalyst Pharmaceuticals's revenue per employee in the last FY averaged $2.7M, while opex per employee averaged $1.3M for the same period.

Catalyst Pharmaceuticals's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Catalyst Pharmaceuticals's rule of X is 67% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Catalyst Pharmaceuticals and other 15K+ public comps

Catalyst Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	8%	XXX	12%	XXX	XXX	XXX
EBITDA Margin	48%	XXX	47%	XXX	XXX	XXX
EBITDA Growth	12%	XXX	51%	XXX	XXX	XXX
Rule of 40	38%	XXX	55%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	67%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$2.7M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	23%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	46%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial